Targeted Enzymatic VLP-Nanoreactors with β-Glucocerebrosidase Activity as Potential Enzyme Replacement Therapy for Gaucher's Disease. 2022

Kanchan Chauhan, and Cindy N Olivares-Medina, and Maria V Villagrana-Escareño, and Karla Juárez-Moreno, and Rubén D Cadena-Nava, and Ana G Rodríguez-Hernández, and Rafael Vazquez-Duhalt
Centro de Nanociencias y Nanotecnología, Universidad Nacional Autónoma de México, Km 107 carretera Tijuana-Ensenada, 22860, Ensenada, Baja California, Mexico.

Gaucher disease is a genetic disorder and the most common lysosomal disease caused by the deficiency of enzyme β-glucocerebrosidase (GCase). Although enzyme replacement therapy (ERT) is successfully applied using mannose-exposed conjugated glucocerebrosidase, the lower stability of the enzyme in blood demands periodic intravenous administration that adds to the high cost of treatment. In this work, the enzyme β-glucocerebrosidase was encapsulated inside virus-like nanoparticles (VLPs) from brome mosaic virus (BMV), and their surface was functionalized with mannose groups for targeting to macrophages. The VLP nanoreactors showed significant GCase catalytic activity. Moreover, the Michaelis-Menten constants for the free GCase enzyme (KM =0.29 mM) and the functionalized nanoreactors (KM =0.32 mM) were similar even after chemical modification. Importantly, the stability of enzymes under physiological conditions (pH 7.4, 37 °C) was enhanced by ≈11-fold after encapsulation; this is beneficial for obtaining a higher blood circulation half-life, which may decrease the cost of therapy by reducing the requirement of multiple intravenous injections. Finally, the mannose receptor targeted enzymatic nanoreactors showed enhanced internalization into macrophage cells. Thus, the catalytic activity and cell targeting suggest the potential of these nanoreactors in ERT of Gaucher's disease.

UI MeSH Term Description Entries
D008358 Mannose A hexose or fermentable monosaccharide and isomer of glucose from manna, the ash Fraxinus ornus and related plants. (From Grant & Hackh's Chemical Dictionary, 5th ed & Random House Unabridged Dictionary, 2d ed) D-Mannose,Mannopyranose,Mannopyranoside,D Mannose
D005776 Gaucher Disease An autosomal recessive disorder caused by a deficiency of acid beta-glucosidase (GLUCOSYLCERAMIDASE) leading to intralysosomal accumulation of glycosylceramide mainly in cells of the MONONUCLEAR PHAGOCYTE SYSTEM. The characteristic Gaucher cells, glycosphingolipid-filled HISTIOCYTES, displace normal cells in BONE MARROW and visceral organs causing skeletal deterioration, hepatosplenomegaly, and organ dysfunction. There are several subtypes based on the presence and severity of neurological involvement. Cerebroside Lipidosis Syndrome,Gaucher Disease Type 1,Gaucher Disease Type 2,Glucocerebrosidase Deficiency Disease,Glucosylceramide Beta-Glucosidase Deficiency Disease,Neuronopathic Gaucher Disease,Acid beta-Glucosidase Deficiency,Acid beta-Glucosidase Deficiency Disease,Acute Neuronopathic Gaucher Disease,Chronic Gaucher Disease,GBA Deficiency,Gaucher Disease Type 3,Gaucher Disease, Acute Neuronopathic,Gaucher Disease, Acute Neuronopathic Type,Gaucher Disease, Chronic,Gaucher Disease, Chronic Neuronopathic Type,Gaucher Disease, Infantile,Gaucher Disease, Infantile Cerebral,Gaucher Disease, Juvenile,Gaucher Disease, Juvenile and Adult, Cerebral,Gaucher Disease, Neuronopathic,Gaucher Disease, Non-Neuronopathic Form,Gaucher Disease, Noncerebral Juvenile,Gaucher Disease, Subacute Neuronopathic Form,Gaucher Disease, Subacute Neuronopathic Type,Gaucher Disease, Type 1,Gaucher Disease, Type 2,Gaucher Disease, Type 3,Gaucher Disease, Type I,Gaucher Disease, Type II,Gaucher Disease, Type III,Gaucher Splenomegaly,Gaucher Syndrome,Gaucher's Disease,Gauchers Disease,Glucocerebrosidase Deficiency,Glucocerebrosidosis,Glucosyl Cerebroside Lipidosis,Glucosylceramidase Deficiency,Glucosylceramide Beta-Glucosidase Deficiency,Glucosylceramide Lipidosis,Infantile Gaucher Disease,Kerasin Histiocytosis,Kerasin Lipoidosis,Kerasin thesaurismosis,Lipoid Histiocytosis (Kerasin Type),Non-Neuronopathic Gaucher Disease,Subacute Neuronopathic Gaucher Disease,Type 1 Gaucher Disease,Type 2 Gaucher Disease,Type 3 Gaucher Disease,Cerebroside Lipidoses, Glucosyl,Cerebroside Lipidosis Syndromes,Cerebroside Lipidosis, Glucosyl,Deficiencies, GBA,Deficiencies, Glucocerebrosidase,Deficiency Disease, Glucocerebrosidase,Deficiency Diseases, Glucocerebrosidase,Deficiency, GBA,Deficiency, Glucocerebrosidase,Disease, Chronic Gaucher,Disease, Gaucher,Disease, Gaucher's,Disease, Gauchers,Disease, Glucocerebrosidase Deficiency,Disease, Infantile Gaucher,Disease, Juvenile Gaucher,Disease, Neuronopathic Gaucher,Disease, Non-Neuronopathic Gaucher,Diseases, Gauchers,Diseases, Glucocerebrosidase Deficiency,GBA Deficiencies,Gaucher Disease, Non Neuronopathic Form,Gaucher Disease, Non-Neuronopathic,Gauchers Diseases,Glucocerebrosidase Deficiencies,Glucocerebrosidase Deficiency Diseases,Glucocerebrosidoses,Glucosyl Cerebroside Lipidoses,Glucosylceramide Lipidoses,Histiocytoses, Kerasin,Histiocytoses, Lipoid (Kerasin Type),Histiocytosis, Kerasin,Histiocytosis, Lipoid (Kerasin Type),Juvenile Gaucher Disease,Kerasin Histiocytoses,Kerasin Lipoidoses,Kerasin thesaurismoses,Lipidoses, Glucosyl Cerebroside,Lipidoses, Glucosylceramide,Lipidosis Syndrome, Cerebroside,Lipidosis Syndromes, Cerebroside,Lipidosis, Glucosyl Cerebroside,Lipidosis, Glucosylceramide,Lipoid Histiocytoses (Kerasin Type),Lipoidoses, Kerasin,Lipoidosis, Kerasin,Non Neuronopathic Gaucher Disease,Splenomegaly, Gaucher,Syndrome, Cerebroside Lipidosis,Syndrome, Gaucher,Syndromes, Cerebroside Lipidosis,thesaurismoses, Kerasin,thesaurismosis, Kerasin
D005962 Glucosylceramidase A glycosidase that hydrolyzes a glucosylceramide to yield free ceramide plus glucose. Deficiency of this enzyme leads to abnormally high concentrations of glucosylceramide in the brain in GAUCHER DISEASE. EC 3.2.1.45. Glucocerebrosidase,Acid beta-Glucosidase,Glucocerebroside beta-Glucosidase,Glucosyl Ceramidase,Glucosylceramide beta-Glucosidase,Glucosylsphingosine Glucosyl Hydrolase,beta-Glucocerebrosidase,Acid beta Glucosidase,Ceramidase, Glucosyl,Glucocerebroside beta Glucosidase,Glucosyl Hydrolase, Glucosylsphingosine,Glucosylceramide beta Glucosidase,Hydrolase, Glucosylsphingosine Glucosyl,beta Glucocerebrosidase,beta-Glucosidase, Acid,beta-Glucosidase, Glucocerebroside,beta-Glucosidase, Glucosylceramide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D056947 Enzyme Replacement Therapy Therapeutic replacement or supplementation of defective or missing enzymes to alleviate the effects of enzyme deficiency (e.g., GLUCOSYLCERAMIDASE replacement for GAUCHER DISEASE). Enzyme Replacement Therapies,Replacement Therapies, Enzyme,Replacement Therapy, Enzyme,Therapies, Enzyme Replacement,Therapy, Enzyme Replacement
D036103 Nanotechnology The development and use of techniques to study physical phenomena and construct structures in the nanoscale size range or smaller. Nanotechnologies

Related Publications

Kanchan Chauhan, and Cindy N Olivares-Medina, and Maria V Villagrana-Escareño, and Karla Juárez-Moreno, and Rubén D Cadena-Nava, and Ana G Rodríguez-Hernández, and Rafael Vazquez-Duhalt
May 1991, The New England journal of medicine,
Kanchan Chauhan, and Cindy N Olivares-Medina, and Maria V Villagrana-Escareño, and Karla Juárez-Moreno, and Rubén D Cadena-Nava, and Ana G Rodríguez-Hernández, and Rafael Vazquez-Duhalt
October 2015, Plant biotechnology journal,
Kanchan Chauhan, and Cindy N Olivares-Medina, and Maria V Villagrana-Escareño, and Karla Juárez-Moreno, and Rubén D Cadena-Nava, and Ana G Rodríguez-Hernández, and Rafael Vazquez-Duhalt
November 1974, The New England journal of medicine,
Kanchan Chauhan, and Cindy N Olivares-Medina, and Maria V Villagrana-Escareño, and Karla Juárez-Moreno, and Rubén D Cadena-Nava, and Ana G Rodríguez-Hernández, and Rafael Vazquez-Duhalt
January 2008, Pharmazie in unserer Zeit,
Kanchan Chauhan, and Cindy N Olivares-Medina, and Maria V Villagrana-Escareño, and Karla Juárez-Moreno, and Rubén D Cadena-Nava, and Ana G Rodríguez-Hernández, and Rafael Vazquez-Duhalt
December 1997, Bailliere's clinical haematology,
Kanchan Chauhan, and Cindy N Olivares-Medina, and Maria V Villagrana-Escareño, and Karla Juárez-Moreno, and Rubén D Cadena-Nava, and Ana G Rodríguez-Hernández, and Rafael Vazquez-Duhalt
December 1991, The New England journal of medicine,
Kanchan Chauhan, and Cindy N Olivares-Medina, and Maria V Villagrana-Escareño, and Karla Juárez-Moreno, and Rubén D Cadena-Nava, and Ana G Rodríguez-Hernández, and Rafael Vazquez-Duhalt
June 1994, Harefuah,
Kanchan Chauhan, and Cindy N Olivares-Medina, and Maria V Villagrana-Escareño, and Karla Juárez-Moreno, and Rubén D Cadena-Nava, and Ana G Rodríguez-Hernández, and Rafael Vazquez-Duhalt
December 1976, Proceedings of the National Academy of Sciences of the United States of America,
Kanchan Chauhan, and Cindy N Olivares-Medina, and Maria V Villagrana-Escareño, and Karla Juárez-Moreno, and Rubén D Cadena-Nava, and Ana G Rodríguez-Hernández, and Rafael Vazquez-Duhalt
August 1977, Proceedings of the National Academy of Sciences of the United States of America,
Kanchan Chauhan, and Cindy N Olivares-Medina, and Maria V Villagrana-Escareño, and Karla Juárez-Moreno, and Rubén D Cadena-Nava, and Ana G Rodríguez-Hernández, and Rafael Vazquez-Duhalt
October 1995, Pediatrics,
Copied contents to your clipboard!